Petros Christopoulos, V. E. (2018). EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ NSCLC. Wiley-Blackwell.
Chicago Style (17th ed.) CitationPetros Christopoulos, Volker Endris. EML4-ALK Fusion Variant V3 Is a High-risk Feature Conferring Accelerated Metastatic Spread, Early Treatment Failure and Worse Overall Survival in ALK+ NSCLC. Wiley-Blackwell, 2018.
MLA (9th ed.) CitationPetros Christopoulos, Volker Endris. EML4-ALK Fusion Variant V3 Is a High-risk Feature Conferring Accelerated Metastatic Spread, Early Treatment Failure and Worse Overall Survival in ALK+ NSCLC. Wiley-Blackwell, 2018.
Warning: These citations may not always be 100% accurate.